pharma · Generalized Pustular Psoriasis · Schizophrenia · VNDA
Vanda Pharmaceuticals Netherlands
Vanda Pharmaceuticals Netherlands B.V.
Vanda Pharmaceuticals Netherlands is a pharma organization headquartered in Washington, USA. It trades on NYSE under ticker VNDA. Primary therapeutic focus areas include Generalized Pustular Psoriasis, Schizophrenia, Maj
2200 Pennsylvania Avenue NW, Suite 300E, Washington, DC 20037, US HQ
2003 Founded
600 Employees
Public company Type
VNDA · NYSE Ticker
Company details
- Status
- Public
- HQ
- 2200 Pennsylvania Avenue NW, Suite 300E, Washington, DC 20037, US
- Founded
- 2003
- Employees
- 600
- Programs
- 60
- Drugs
- 19
- Patents
- 96
Double-blind 200 mg imsidolimab
Phase 3 · small molecule · Generalized Pustular Psoriasis
Double-blind 200 mg imsidolimab for Generalized Pustular Psoriasis is a Phase 3 program (small_molecule) at Vanda Pharmaceuticals Netherlands B.V. with 1 ClinicalTrials.gov record(s).
Internal code ANB019-302
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- Vanda Pharmaceuticals Netherlands B.V.
- Phase
- Phase 3
- Modality
- small_molecule
- Indication
- Generalized Pustular Psoriasis
- Status
- terminated
- Trials
- 1